<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987219</url>
  </required_header>
  <id_info>
    <org_study_id>13-00004</org_study_id>
    <nct_id>NCT01987219</nct_id>
  </id_info>
  <brief_title>The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia</brief_title>
  <official_title>The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of bronchodilator therapy on respiratory function. Our overall goal is
      to determine whether, in patients with familial dysautonomia (FD), there is a component of
      airway obstruction that is reversible. To this end, we will evaluate airway resistance before
      and after receiving the anti-cholinergic ipratropium (Atrovent ®) and the beta-2-agonist
      albuterol (ProVentil®/Ventolin®). We predict that the response to either drug will depend on
      the underlying level of sympathetic and parasympathetic activity and airway tone. We will
      then determine the cardiovascular effects of inhaled ipratropium and albuterol in patients
      with FD. Because patients with FD have fewer sympathetic neurons and denervation
      supersenstivity, we predict that following albuterol inhalation, there will be non-selective
      activation of alpha-1-adrenergic receptors. Furthermore, because of a congenital defect in
      the afferent baroreceptor neurons that sense blood pressure, we suspect that the resulting
      vasoconstriction will be unopposed leading to a pressor effect. We hypothesize that
      inhalation of the anti-cholinergic ipratopium will produce little rise in heart rate, due to
      the extent of parasympathetic denervation to the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial dysautonomia (FD) is a rare fatal autosomal recessive disease caused by a deficiency
      of the protein IKAP.1 This results in a selective developmental defect that affects mostly
      afferent (sensory) neurons including those in the dorsal root ganglia and cranial nerves.2, 3
      We have shown recently that the protein deficiency impairs the development of afferent
      baroreceptor pathways, leaving the sympathetic efferent neurons reduced in number but
      functionally active. This results in the complete failure to detect and buffer fluctuations
      in blood pressure leading to volatile hypertension. In addition to the afferent baroreflex
      pathways, the deficiency of IKAP during embroyogenesis also affects the function of the
      chemoreflex pathways. As a result, patients fail to increase ventilation adequately in
      response to hypoxia and hypercapnia.4 As well as the impairment of the neurological
      mechanisms that regulate breathing, patients with FD also have a combination of obstructive,
      restrictive and probably also neuromuscular lung disease. Failure to coordinate swallowing
      results in recurrent bouts of aspiration pneumonia occurring from birth.5, 6 Imaging studies
      show that almost all patients with FD have bronchial wall thickening, atelectasis and almost
      30% have bronchiectasis7. Pulmonary function tests show air flow limitation and associated
      lung restriction with reduction in diffusion capacity12. Sudden attacks of asthma like
      wheezing are common 8 and frequently associated with emotional upset,5 a time when
      sympathetic outflow to the vasculature is increased heightened.3 There is also a component of
      restrictive lung disease, with a very high incidence of scoliosis, which frequently begins at
      an early age. Complicating matters further, many patients opt to undergo spine fusion
      surgery, 9 which could potentially worsen further chest wall compliance.10 Patients with FD
      also lack muscle spindles, 2 making it likely that they have neuromuscular abnormalities
      arising from the absence of proprioceptive feedback from the respiratory muscles involved in
      the coordination of breathing.

      Severe respiratory disease is a leading cause of death in patients with FD and many are
      treated empirically with inhaled bronchodilators. It is not known, however, whether these
      drugs are effective at reversing increased airway resistance. Hence, there is an urgent need
      to understand if the short acting beta-2-adrenergic agonist albuterol and the anticholinergic
      ipratropium, are effective bronchodilators. Furthermore, because treatment with these agents
      has potential cardiovascular side effects, we will also analyze their effects on blood
      pressure, heart rate and cardiac output.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of Forced Vital Capacity</measure>
    <time_frame>Pre and 30 minutes post study drug administration</time_frame>
    <description>FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline</measure>
    <time_frame>Pre and 30 minutes post study drug administration</time_frame>
    <description>The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume (FEV) From Baseline</measure>
    <time_frame>Pre and 30 post study drug admistration</time_frame>
    <description>Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Flow Between 25-75% (FEF25-75)</measure>
    <time_frame>pre and 30 minutes post intervention</time_frame>
    <description>FEF25-75 is measured in liters of air per second at 25-75%</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Familial Dysautonomia</condition>
  <arm_group>
    <arm_group_label>Albuterol-sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium-bromide (Atrovent ®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Saline solution 3 cc NA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol-sulphate</intervention_name>
    <description>Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours</description>
    <arm_group_label>Albuterol-sulphate</arm_group_label>
    <other_name>(Proventil ®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium-bromide</intervention_name>
    <description>Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.</description>
    <arm_group_label>Ipratropium-bromide (Atrovent ®)</arm_group_label>
    <other_name>(Atrovent ®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Saline solution 3 cc NA</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of familial dysautonomia (Riley-Day syndrome, hereditary sensory and
             autonomic neuropathy type III) 2. Ages 12 and older: Bronchodilators are routinely
             used in young children with FD therefore they should be included in this study. The
             spirometry maneuver is highly dependent on patient cooperation and effort, and FD
             patients already have limitations that make the spirometry maneuver more problematic
             to perform such as difficulty with mouth closure and drooling. Therefore, we believe
             age 12 is a suitable age for FD patients to be included in this study, though in the
             general population reliable results can be obtained from the age of 6 and sometimes
             even younger.

             3. Patients using Albuterol or Ipratroprium will be included in the study but will be
             instructed not to take the 24 hours prior to the testing. It is a common practice in
             clinical medicine to withhold the inhalation drugs prior to performing pulmonary
             function tests in order to evaluate the response to bronchodilators, an integral part
             of the test. Patients with an acute respiratory exacerbation will not be enrolled, as
             withholding bronchodilators would not be advisable.

             4. Patients who are taking medications that might affect autonomic function such as
             anti-hypertensives, beta-blockers, midodrine and florinef will be included in the
             study and we will record current medication regimen and the time the medication was
             taken.

        Exclusion Criteria:

        - 1. Patients who last used inhaled anti-cholinergics or beta-2-agonists within 4-half
        lives of the drug.

        2. Patients with an acute respiratory illness 3. Patients who have had lobectomies. 4.
        Patients using oxygen therapy throughout the day. 5. Patients who are unable to comply with
        the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>April 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2016</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>familial dysautonomia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Dysautonomia, Familial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifteen patients with Familial Dysautonomia were enrolled into the study between March 2013 and December 2015. The study was conducted at the NYU Dsyautonomia Center and Israeli FD center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ipratropium; Alubterol; Placebo</title>
          <description>Participants in this group received ipratropium followed by albuterol followed by placebo</description>
        </group>
        <group group_id="P2">
          <title>Albuterol; Placebo; Ipratropium</title>
          <description>Participants in this group received albuterol followed by placebo followed by ipratropium</description>
        </group>
        <group group_id="P3">
          <title>Albuterol; Ipratropium; Placebo</title>
          <description>Participants in this group received albuterol followed by ipratropium followed by placebo</description>
        </group>
        <group group_id="P4">
          <title>Placebo; Ipratropium; Albuterol</title>
          <description>Participants in this group received placebo followed by ipratropium followed by albuterol</description>
        </group>
        <group group_id="P5">
          <title>Placebo; Albuterol; Ipratropium</title>
          <description>Participants in this group received placebo followed by albuterol followed by ipratropium</description>
        </group>
        <group group_id="P6">
          <title>Ipratropium; Placebo; Albuterol</title>
          <description>Participants in this group received ipratropium followed by placebo followed by albuterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ipratropium; Alubterol; Placebo</title>
        </group>
        <group group_id="B2">
          <title>Albuterol; Placebo; Ipratropium</title>
        </group>
        <group group_id="B3">
          <title>Albuterol; Ipratropium; Placebo</title>
        </group>
        <group group_id="B4">
          <title>Placebo; Ipratropium; Albuterol</title>
        </group>
        <group group_id="B5">
          <title>Placebo; Albuterol; Ipratropium</title>
        </group>
        <group group_id="B6">
          <title>Ipratropium; Placebo; Albuterol</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, not of Hispanic-American Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Forced Vital Capacity</title>
        <description>FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function.</description>
        <time_frame>Pre and 30 minutes post study drug administration</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol-sulphate</title>
            <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours
Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium-bromide (Atrovent ®)</title>
            <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.pium-bromide
Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Saline solution 3 cc NA
placebo: Saline solution 3 cc NA</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Forced Vital Capacity</title>
          <description>FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function.</description>
          <population>Per protocol</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="13.6"/>
                    <measurement group_id="O2" value="4.7" spread="10.9"/>
                    <measurement group_id="O3" value="0.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline</title>
        <description>The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s).</description>
        <time_frame>Pre and 30 minutes post study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albuterol-sulphate</title>
            <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours
Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium-bromide (Atrovent ®)</title>
            <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.pium-bromide
Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Saline solution 3 cc NA
placebo: Saline solution 3 cc NA</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline</title>
          <description>The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s).</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="18.6"/>
                    <measurement group_id="O2" value="-19.5" spread="15.5"/>
                    <measurement group_id="O3" value="-1.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume (FEV) From Baseline</title>
        <description>Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation.</description>
        <time_frame>Pre and 30 post study drug admistration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albuterol-sulphate</title>
            <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours
Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium-bromide (Atrovent ®)</title>
            <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.pium-bromide
Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Saline solution 3 cc NA
placebo: Saline solution 3 cc NA</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume (FEV) From Baseline</title>
          <description>Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" spread="12.06"/>
                    <measurement group_id="O2" value="4.81" spread="9.9"/>
                    <measurement group_id="O3" value="-0.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Flow Between 25-75% (FEF25-75)</title>
        <description>FEF25-75 is measured in liters of air per second at 25-75%</description>
        <time_frame>pre and 30 minutes post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albuterol-sulphate</title>
            <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours
Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium-bromide (Atrovent ®)</title>
            <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.pium-bromide
Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Saline solution 3 cc NA
placebo: Saline solution 3 cc NA</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Flow Between 25-75% (FEF25-75)</title>
          <description>FEF25-75 is measured in liters of air per second at 25-75%</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="30.6"/>
                    <measurement group_id="O2" value="11.5" spread="36.1"/>
                    <measurement group_id="O3" value="-2.99" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and Other [Not Including Serious] Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Albuterol-sulphate</title>
          <description>Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours
Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 – 30 mins. Mean duration of effect 3 hours</description>
        </group>
        <group group_id="E2">
          <title>Ipratropium-bromide (Atrovent ®)</title>
          <description>IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.pium-bromide
Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 – 90 mins. Duration of effect 2 – 4 hours.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo Saline solution 3 cc NA
placebo: Saline solution 3 cc NA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Horacio Kaufmann</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>212 263 7225</phone>
      <email>horacio.kaufmann@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

